Search Results - Javier Loscertales
- Showing 1 - 11 results of 11
-
1
Clinical outcome and prognostic factors of patients with Richter syndrome: real‐world study of the Spanish Chronic Lymphocytic Leukemia Study Group (GELLC) by Pau Abrisqueta, Julio Delgado, Miguel Alcoceba, Ana Carla Oliveira, Javier Loscertales, José‐Ángel Hernández‐Rivas, Christelle Ferrà, Raúl Córdoba, Lucrecia Yáñez, Ángeles Medina, Cristina Motlló, Gloria Iacoboni, Guillermo Villacampa, Marcos González, Francesc Bosch
Published 2020Artigo -
2
Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase <scp>III</scp> trial by Wolfgang Knauf, Toshko Lissitchkov, Ali Aldaoud, A. M. Liberati, Javier Loscertales, Raoul Herbrecht, Gunnar Juliusson, Gerhard Postner, Liana Gercheva, Vesselina Goranova‐Marinova, Martin Becker, Hans‐Joerg Fricke, Françoise Huguet, Ilaria Del Giudice, Peter Klein, K Merkle, Marco Montillo
Published 2012Artigo -
3
Randomized phase 2 study of otlertuzumab and bendamustine <i>versus</i> bendamustine in patients with relapsed chronic lymphocytic leukaemia by Tadeusz Robak, Andrzej Hellmann, Janusz Kłoczko, Javier Loscertales, Ewa Lech‐Marańda, John M. Pagel, Anthony R. Mato, John C. Byrd, Farrukh T. Awan, Holger Hebart, Jose A. García‐Marco, Brian T. Hill, Michael Hallek, Amy J. Eisenfeld, Scott Stromatt, Ulrich Jaeger
Published 2016Artigo -
4
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab fo... by Paula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, Sebastian Grosicki, Marie‐Sarah Dilhuydy, Ann Janssens, Javier Loscertales, Simon Rule, André Goy, Shana Traina, Eric K. H. Chan, Joris Diels, Nishan Sengupta, Michelle Mahler, Mariya Salman, Angela Howes, Asher Chanan‐Khan
Published 2018Artigo -
5
Phase III Randomized Study of Bendamustine Compared With Chlorambucil in Previously Untreated Patients With Chronic Lymphocytic Leukemia by Wolfgang Knauf, Toshko Lissichkov, Ali Aldaoud, A. M. Liberati, Javier Loscertales, Raoul Herbrecht, Gunnar Juliusson, Gerhard Postner, Liana Gercheva, Vesselina Goranova‐Marinova, Martin Becker, Hans-Joerg Fricke, Françoise Huguet, Ilaria Del Giudice, Peter Klein, Lothar Tremmel, K Merkle, Marco Montillo
Published 2009Artigo -
6
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Le... by Tadeusz Robak, Anna Dmoszyńska, Philippe Solal‐Céligny, Krzysztof Warzocha, Javier Loscertales, John Catalano, B. V. Аfanasiev, Loree Larratt, Christian H. Geisler, Marco Montillo, Ilya Zyuzgin, Peter Ganly, Caroline Dartigeas, András Rosta, Jörg Maurer, Myriam Mendila, M. Wayne Saville, Nancy Valente, Michael Wenger, Moiseev Si
Published 2010Artigo -
7
Effect of FCGR2A and FCGR3A variants on CLL outcome by David Dornan, Olivia Spleiss, Ru-Fang Yeh, Guillemette Duchâteau-Nguyen, Annika Dufour, Jianguo Zhi, Tadeusz Robak, Moiseev Si, Anna Dmoszyńska, Philippe Solal‐Céligny, Krzysztof Warzocha, Javier Loscertales, John Catalano, B. V. Аfanasiev, Loree Larratt, Viktor Rossiev, Isabelle Bence‐Bruckler, Christian H. Geisler, Marco Montillo, Michael Wenger, Maja Weisser
Published 2010Artigo -
8
S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY by Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna‐Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Eva Diana Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Published 2023Artigo -
9
Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic... by Graeme Fraser, Asher Chanan‐Khan, Fatih Demırkan, Rodrigo Santucci Silva, Sebastian Grosicki, Ann Janssens, Jiřı́ Mayer, Nancy L. Bartlett, Marie‐Sarah Dilhuydy, Javier Loscertales, Abraham Avigdor, Simon Rule, Olga Samoilova, Miguel Arturo Pavlovsky, André Goy, Anthony R. Mato, Michael Hallek, Mariya Salman, Monelle Tamegnon, Steven Sun, Anne Connor, Kerri Nottage, Natasha Schuier, Sriram Balasubramanian, Angela Howes, Paula Cramer
Published 2020Artigo -
10
Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma by Graeme Fraser, Paula Cramer, Fatih Demırkan, Rodrigo Santucci Alves da Silva, Sebastian Grosicki, Alexander Pristupa, Ann Janssens, Jiřı́ Mayer, Nancy L. Bartlett, M.S. Dilhuydy, Halyna Pylypenko, Javier Loscertales, Abraham Avigdor, Simon Rule, Diego Villa, Olga Samoilova, P. Panagiotidis, André Goy, Miguel Arturo Pavlovsky, Claes Karlsson, Michael Hallek, Michelle Mahler, Mariya Salman, Steven Sun, Charles E. Phelps, Sriram Balasubramanian, Angela Howes, Asher Chanan‐Khan
Published 2018Artigo -
11
Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study by Othman Al‐Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl‐Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P. Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva Diana Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Published 2024Artigo
Search Tools:
Related Subjects
Chronic lymphocytic leukemia
Internal medicine
Leukemia
Medicine
Gastroenterology
Oncology
Bendamustine
Chemotherapy
Rituximab
Cyclophosphamide
Lymphoma
Chlorambucil
Confidence interval
Hazard ratio
Adverse effect
Alternative medicine
Fludarabine
Ibrutinib
Neutropenia
Ofatumumab
Pathology
Placebo
Alemtuzumab
Clinical endpoint
Immunology
Obinutuzumab
Surgery
Transplantation
Venetoclax
Antibody